A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Phase

1/2

Condition

Joint Injuries

Collagen Vascular Diseases

Arthritis And Arthritic Pain (Pediatric)

Treatment

N/A

Clinical Study ID

NCT05588908

SSGJ-613-AG-Ib/II-01

Ages 18-65
All Genders

Study Summary

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Must be 18 Years to 65 Years, both male and female
Meeting the American College of Rheumatology (ACR) 2015 criteria for theclassification of acute arthritis of primary gout.
Presence of acute gout flare for no longer than 7 days
Baseline pain intensity > or = to 50 mm on the 0-100 mm VAS
Contraindicated for, intolerant or unresponsive to NSAIDs, colchicine or both

Exclusion

Exclusion Criteria:

Secondary gout (such as gout caused by chemotherapy, transplant gout, etc.)
Evidence/suspicion of infectious/septic arthritis, or other acute inflammatoryarthritis
Presence of severe renal function impairment
Intolerance of subcutaneous and intramuscular injection
Known presence or suspicion of active or recurrent bacterial, fungal or viralinfection at the time of enrollment
History of malignant tumor within 5 years before screening
Live vaccinations within 3 months prior to the start of the study
Use of forbidden therapy

Study Design

June 29, 2022

November 30, 2023

Study Description

The phase Ib study is a multi-center, open label, dose escalation study examining the effect of recombinant anti-IL-1β humanized monoclonal antibody injection and to determine the target dose of phase II for the treatment of acute flare in Chinese gout patients in whom non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine are contraindicated, are not tolerated, or do not provide an adequate response. There are 3 dose groups (100 mg、200 mg and 300 mg) in phase Ib and 10 participants in each group.

The phase II study is a dose-ranging, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel-group study examining the effect of 2 dose regimens (200 mg and 300 mg, based on the outcome of phase Ib) of recombinant anti-IL-1β humanized monoclonal antibody injection versus compound betamethasone injection for the treatment of acute flare in Chinese gout patients in whom NSAIDs and/or colchicine are contraindicated, are not tolerated, or do not provide an adequate response. The phase II recommended dose of SSGJ-613 in subjects with acute gouty was determined according to the phase Ib interim analysis results.

Connect with a study center

Site 02
Wuhan, Hubei 430030
China
Active - Recruiting
Site 03
Linyi, Shandong 276100
China
Site Not Available
Site 01
Shanghai, Shanghai 200040
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.